Judo Bio Secures $100M Financing to Advance Kidney-Targeted Oligonucleotide Medicines
Slice of Healthcare Team
Oct 10, 2024
Key Highlights
- Judo Bio secures $100M in initial financing for kidney-targeted medicines.
- Series A co-led by Atlas Venture, TCG, and Droia Ventures.
- Appointment of Rajiv Patni, M.D., as Chief Executive Officer and Board Director.
- Lead platform STRIKE advances novel megalin-STRIKER siRNA therapeutics.
- Initial focus on silencing SLCs to address systemic diseases.
Source: Business Wire
Notable Quotes
“ The Judo team should be applauded for their achievements to date. In a short period, the company has developed a novel platform, demonstrated potent and selective gene knockdown in specific kidney regions, and constructed a pipeline of compelling programs that we are excited to see advanced towards the clinic. ”
Kevin Bitterman, Ph.D., Partner at Atlas Venture
“ With Judo Bio’s discovery of novel ligands that result in oligonucleotide delivery to specific kidney cells, diseases that were intractable to this approach may now be within reach. ”
John Maraganore, Ph.D., Founder and former CEO at Alnylam
“ With the Series A funding in hand, Judo can build on its solid foundation and nominate a series of development candidates, with efficient and timely proof-of-concept data readouts. ”
Rajiv Patni, M.D., CEO at Judo Bio
-2e14ed90-63f5-4ce1-84fc-3fa9506b84be.png&w=3840&q=75)
